Asakura 2005.

Methods	Four‐week double blind, single‐centre, randomised study.
Participants	Psychiatric in‐ and outpatients meeting major depressive disorder or other affective disorder according to DSM‐IV. Baseline HRSD score: 20.02 (SD 6.60). Age: 20 years old or more, mean 41.3 years old (SD 13.7). Exclusion criteria: treated with any antidepressants for the current depressive episode.
Interventions	Fluvoxamine: 158 participants. Imipramine: 161 participants. Fluvoxamine dose range: 50‐150 mg/day. Imipramine dose range: 75‐150 mg/day.
Outcomes	HRSD‐17, CGI. Total dropout.
Funded by pharmaceutical companies	Funded by pharmaceutical companies market fluvoxamine and comparator drug.
Fluvoxamine as an investigational or comparator drug	As an investigational drug.
Notes	Almost all the patients were drug naive outpatients. 17% (54/309) of participants were with dysthymic disorder, depressive disorder not otherwise specified, bipolar II disorder or major depressive disorder with psychotic features.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "patients were randomized", no further details.
Allocation concealment (selection bias)	Unclear risk	No details.
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Quote: "double blind", no further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Study endpoint: 9/158 missing from fluvoxamine group; 12/161 missing from control group.
Selective reporting (reporting bias)	Unclear risk	Insufficient information to permit judgement.